Processa Pharmaceuticals Accounts Payable

Processa Pharmaceuticals (PCSA) currently reports a accounts payable of $840K as of March 2026. That compares with $550K in the prior-year period — up 52.1% year over year. Use the charts on this page to explore Processa Pharmaceuticals's accounts payable history and peer comparisons.

Processa Pharmaceuticals's accounts payable increased from $550K to $840K — a 52.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Processa Pharmaceuticals reported $840K in accounts payable as of March 2026. That compares with $550K in the prior-year period — up 52.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $840K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Processa Pharmaceuticals, and consider following PCSA for alerts when major investors trade the stock.

Processa Pharmaceuticals is classified in the Industrials sector. On accounts payable, it currently shows $840K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing PCSA with unrelated industries.